Australian industry disappointed as govt snubs stability deal
This article was originally published in Scrip
Medicines Australia has expressed its disappointment at the health minister's decision not to sign a strategic agreement that would have provided the Australian industry with some policy stability over the next five years in return for agreeing to support medicines access and sustainability measures including price cuts to medicines listed on the Pharmaceutical Benefits Scheme.
You may also be interested in...
Early interaction with the European Medicines Agency is recommended if companies are planning to incorporate digital technologies into their drug development plans.
The latest global vaccines summit has seen the launch of a new mechanism designed to spur the development of new coronavirus vaccines and ensure they are made available, particularly in low- and middle-income countries.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.